Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Pathways of impending disease flare in African-American systemic lupus erythematosus patients.

Munroe ME, Vista ES, Merrill JT, Guthridge JM, Roberts VC, James JA.

J Autoimmun. 2017 Mar;78:70-78. doi: 10.1016/j.jaut.2016.12.005. Epub 2017 Feb 2.

PMID:
28162788
2.

Decreased Gαq expression in T cells correlates with enhanced cytokine production and disease activity in systemic lupus erythematosus.

He Y, Huang Y, Tu L, Luo J, Yu B, Qian H, Duan L, Shi G.

Oncotarget. 2016 Dec 27;7(52):85741-85749. doi: 10.18632/oncotarget.13903.

3.

Interleukin (IL)-39 [IL-23p19/Epstein-Barr virus-induced 3 (Ebi3)] induces differentiation/expansion of neutrophils in lupus-prone mice.

Wang X, Liu X, Zhang Y, Wang Z, Zhu G, Han G, Chen G, Hou C, Wang T, Ma N, Shen B, Li Y, Xiao H, Wang R.

Clin Exp Immunol. 2016 Nov;186(2):144-156. doi: 10.1111/cei.12840. Epub 2016 Aug 12.

4.

Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus.

Peliçari Kde O, Postal M, Sinicato NA, Peres FA, Fernandes PT, Marini R, Costallat LT, Appenzeller S.

Clinics (Sao Paulo). 2015 May;70(5):313-7. doi: 10.6061/clinics/2015(05)01. Epub 2015 May 1.

5.

The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice.

Rodgers DT, McGrath MA, Pineda MA, Al-Riyami L, Rzepecka J, Lumb F, Harnett W, Harnett MM.

Arthritis Rheumatol. 2015 Apr;67(4):1023-35. doi: 10.1002/art.39004.

6.

Human interleukin-27: wide individual variation in plasma levels and complex inter-relationships with interleukin-17A.

Forrester MA, Robertson L, Bayoumi N, Keavney BD, Barker RN, Vickers MA.

Clin Exp Immunol. 2014 Nov;178(2):373-83. doi: 10.1111/cei.12408.

7.

The glutaredoxin/S-glutathionylation axis regulates interleukin-17A-induced proinflammatory responses in lung epithelial cells in association with S-glutathionylation of nuclear factor κB family proteins.

Nolin JD, Tully JE, Hoffman SM, Guala AS, van der Velden JL, Poynter ME, van der Vliet A, Anathy V, Janssen-Heininger YM.

Free Radic Biol Med. 2014 Aug;73:143-53. doi: 10.1016/j.freeradbiomed.2014.04.028. Epub 2014 May 9.

8.
9.

Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare.

Munroe ME, Vista ES, Guthridge JM, Thompson LF, Merrill JT, James JA.

Arthritis Rheumatol. 2014 Jul;66(7):1888-99. doi: 10.1002/art.38573.

10.

Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis.

Jabbari A, Suárez-Fariñas M, Fuentes-Duculan J, Gonzalez J, Cueto I, Franks AG Jr, Krueger JG.

J Invest Dermatol. 2014 Jan;134(1):87-95. doi: 10.1038/jid.2013.269. Epub 2013 Jun 14. Erratum in: J Invest Dermatol. 2014 Jun;134(6):1780.

11.

Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection.

Wang JM, Ma CJ, Li GY, Wu XY, Thayer P, Greer P, Smith AM, High KP, Moorman JP, Yao ZQ.

Vaccine. 2013 Apr 26;31(18):2238-45. doi: 10.1016/j.vaccine.2013.03.003. Epub 2013 Mar 14.

12.

Differential regulation of interleukin-12 (IL-12)/IL-23 by Tim-3 drives T(H)17 cell development during hepatitis C virus infection.

Wang JM, Shi L, Ma CJ, Ji XJ, Ying RS, Wu XY, Wang KS, Li G, Moorman JP, Yao ZQ.

J Virol. 2013 Apr;87(8):4372-83. doi: 10.1128/JVI.03376-12. Epub 2013 Feb 6.

13.

Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance.

Martino M, Rocchi G, Escelsior A, Fornaro M.

Curr Neuropharmacol. 2012 Jun;10(2):97-123. doi: 10.2174/157015912800604542.

14.

The current concept of T (h) 17 cells and their expanding role in systemic lupus erythematosus.

Perry D, Peck AB, Carcamo WC, Morel L, Nguyen CQ.

Arthritis. 2011;2011:810649. doi: 10.1155/2011/810649. Epub 2011 Mar 22.

15.

Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus.

Dolff S, Abdulahad WH, Westra J, Doornbos-van der Meer B, Limburg PC, Kallenberg CG, Bijl M.

Arthritis Res Ther. 2011;13(5):R157. doi: 10.1186/ar3474. Epub 2011 Sep 29.

16.

The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.

Kahlenberg JM, Kaplan MJ.

Arthritis Res Ther. 2011 Feb 28;13(1):203. doi: 10.1186/ar3264. Review.

17.

HDAC inhibition in lupus models.

Reilly CM, Regna N, Mishra N.

Mol Med. 2011 May-Jun;17(5-6):417-25. doi: 10.2119/molmed.2011.00055. Epub 2011 Feb 11. Review.

Supplemental Content

Support Center